by evivier@statinmed.com | Oct 5, 2022 | Blog
Lowering prescription drug costs and health care costs are among the goals of the Inflation Reduction Act. While changes will not take effect until 2025, what can the biopharmaceutical industry expect? Keshia Maughn, Senior Principal, Strategic Advisory Services at...
by evivier@statinmed.com | Sep 29, 2022 | Mental Health Posters, Presentations
Abstract Background Patient access and healthcare resource use (HCRU) can be impacted by switches from Commercial to Medicaid insurance. Objectives Descriptively assess payor switch rate, HCRU, and costs by race for patients with schizophrenia Methods STATinMED RWD...
by evivier@statinmed.com | Sep 28, 2022 | Hepatology Posters, Infectious Disease Posters, Presentations
Abstract Objective This study assessed baseline characteristics, cost, and healthcare resource utilization (HCRU) of Medicaid-insured patients diagnosed with hepatitis D virus (HDV)/Hepatitis B virus (HBV) coinfection and HBV only. Methods Medicaid-insured patients...
by evivier@statinmed.com | Sep 26, 2022 | Mental Health Posters, Presentations
Abstract Background Tardive dyskinesia (TD), an iatrogenic movement disorder associated with antipsychotic agent (AP) use, is predicted to increase in prevalence, but real-world data are lacking. Methods TD prevalence by year, payer, AP type (for patients with ≥2 AP...
by evivier@statinmed.com | Sep 6, 2022 | Cancer (solid tumor), Publication
Abstract Background: Previous studies report increasing cholangiocarcinoma (CCA) incidence up to 2015. This contemporary retrospective analysis of CCA incidence and mortality in the US from 2001-2017 assessed whether CCA incidence continued to increase beyond...
